Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04176406
Previous Study | Return to List | Next Study

Using fMRI-guided TMS to Increase Central Executive Function in Older Adults (MCI_Sub) (MCI_Sub)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04176406
Recruitment Status : Terminated (Covid-19, Funding ended)
First Posted : November 25, 2019
Last Update Posted : October 8, 2020
Sponsor:
Collaborator:
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Duke University

Brief Summary:

This is an administrative supplement to an existing project "Using fMRI-guided TMS to increase central executive function in older adults: NCT02767323" This award allows extending our existing fMRI-TMS paradigm to patients with a prodromal form of Alzheimer's Disease (AD) known as amnestic Mild Cognitive Impairment (MCI), and investigate the role of brain health factors in mediating the TMS-related memory performance benefits associated with communication between a network of frontoparietal brain regions in these populations.

The focus on focal neurostimulation at only a single site represents a fundamental gap in the approach of memory-based neurostimulation therapies. Neurostimulation affects multiple sites within a cortical network, but these global effects have not been used as targets for stimulation because of limited knowledge about what influence these localized sites have on global changes in brain state. To address this problem, multimodal neuroimaging tools and network modeling approaches developed though the parent U01 project will be used, to demonstrate how focal neurostimulation improves the efficacy of TMS for enhancing memory function. These goals will be addressed in the Administrative Supplement under our two specific aims. First, network-guided TMS will be applied to optimize memory success based in the frontoparietal network (FPN) in a new group of MCI patients. A new form of TMS targeting that involves modeling of the global network to understand how the controllability of a stimulation site evokes changes in widespread brain networks will be tested. Second, structural and functional factors affecting the efficacy of individualized network-guided TMS will be identified to ameliorate deficits in MCI. By creating a multimodal model of neural deficits related to MCI, network-guided TMS will be adjusted to demonstrate how the MCI brain might compensate for these neural deficits. The parent U01 project has made foundational advances towards these goals, as we have demonstrated the ability of to selectively enhance and reduce working memory performance in healthy older adults. In the current Administrative Supplement this paradigm will be extended to a group of MCI participants in order to test the hypothesis that excitatory rTMS to the working memory network can provide positive outcomes for patients with pre-clinical AD. The proposed work will provide an important tool for studying the stability and controllability of network connectivity of memory states in the aging brain, as well as new information on the effectiveness of brain stimulation technologies as a therapeutic approach for cognitive decline.


Condition or disease Intervention/treatment Phase
Mild Cognitive Impairment Device: rTMS Device: Sham rTMS Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: Using fMRI-guided TMS to Increase Central Executive Function in Older Adults (MCI_Sub)
Actual Study Start Date : November 25, 2019
Actual Primary Completion Date : February 27, 2020
Actual Study Completion Date : February 27, 2020

Arm Intervention/treatment
Active Comparator: rTMS over a node within the fronto-parietal network
excitatory 5Hz rTMS will be applied over a node within the fronto-parietal network, defined via network analysis.
Device: rTMS
excitatory 5Hz rTMS will be used

Sham Comparator: Sham rTMS over a node within the fronto-parietal network
electrical sham coil applied over a node within the fronto-parietal network.
Device: Sham rTMS
an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used

Active Comparator: rTMS over the DLPFC
excitatory 5Hz rTMS will be applied over the dorso-lateral prefrontal cortex showing the strongest fMRI activation.
Device: rTMS
excitatory 5Hz rTMS will be used

Sham Comparator: Sham rTMS over the DLPFC
electrical sham coil applied over the DLPFC.
Device: Sham rTMS
an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used




Primary Outcome Measures :
  1. Acute effect of a rTMS session on the performance for a working memory task, as measured by reaction time of correct response (in ms) [ Time Frame: Through study completion, an average of one year ]
    Reaction time of correct response (in ms) will be assessed to evaluate the acute effect of rTMS.

  2. Acute effect of a rTMS session on the performance for a working memory task, as measured by accuracy (in percentage) [ Time Frame: Through study completion, an average of one year ]
    Accuracy (in percentage) will be assessed to evaluate the acute effect of rTMS.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • English Speaking
  • willing to provide consent
  • signed HIPAA authorization
  • clinical consensus for MCI; and/or met inclusion criterial on MoCA, ApoE.

Exclusion Criteria:

  • History of any I DSM IV disorder that is unstable or untreated
  • current or past history of substance abuse or dependence (excluding nicotine)
  • women who are pregnant or breast feeding
  • intracranial implants (e.g. aneurysms clips, shunts, stimulators, cochlear implants, or electrodes
  • increased risk of seizure for any reason, including prior diagnosis of epilepsy, seizure disorder, increased intracranial pressure, or history of significant head trauma greater than mild concussion (History of significant head trauma, including with loss of consciousness for ≥ 30 minutes, alteration of consciousness for up to 24 hours following the event, or post-traumatic amnesia) in the past 10yrs or head injury received after age 65
  • Neurological disorder including, but not limited to: space occupying brain lesion; any history of seizures, history of cerebrovascular accident; cerebral aneurysm , Dementia, Huntington chorea, multiple sclerosis
  • Increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or currently taking medication that are on the strong potential hazard list for rTMS.
  • Subjects taking medications with an ACB score of 3.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04176406


Locations
Layout table for location information
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
Duke University
National Institute on Aging (NIA)
Investigators
Layout table for investigator information
Principal Investigator: Lawrence G Appelbaum Duke University
Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT04176406    
Other Study ID Numbers: Pro00065334_1
First Posted: November 25, 2019    Key Record Dates
Last Update Posted: October 8, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders